Thomas Graney - Vertex Pharmaceuticals CFO, Senior Vice President

VRTX -- USA Stock  

USD 176.14  1.98  1.11%

  President
Mr. Thomas Graney is appointed as Chief Financial Officer, Senior Vice President of the company. Mr. Graney is our Senior Vice President and Chief Financial Officer, a position he has held since September 2017. From August 2014 until he joined Vertex, Mr. Graney served as Chief Financial Officer and Senior Vice President of Finance and Corporationrationrate Strategy for Ironwood Pharmaceuticals, Inc. From January 2010 to August 2014, Mr. Graney served as Worldwide Vice President of Finance and Chief Financial Officer of Ethicon, Inc., a maker of surgical medical devices and subsidiary of Johnson and Johnson. From 1994 to 2010, Mr. Graney served in various roles of increasing responsibility at Johnson Johnson, including most recently as Vice President of Finance for JJ Global Supply Chain. Mr. Graney serves on the board of directors of AC Immune SA, a biopharmaceutical company
Age: 52  President Since 2017  MBA    
617-341-6100  http://www.vrtx.com
Graney holds a BS degree in accounting from the University of Delaware and an M.B.A. in marketing, finance and international business from the Leonard N. Stern School of Business at New York University.

Management Efficiency

The company has return on total asset (ROA) of 9.99 % which means that it generated profit of $9.99 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 56.25 % meaning that it created $56.25 on every $100 dollars invested by stockholders.
The company currently holds 656.95M in liabilities with Debt to Equity (D/E) ratio of 12.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Vertex Pharmaceuticals has Current Ratio of 3.67 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Jeffrey NeedhamPerrigo Company plc
2009
Douglas BoothePerrigo Company plc
2013
Heidi ChenZoetis
2012
Jay MarkowitzRegeneron Pharmaceuticals
2017
Daniel PlewRegeneron Pharmaceuticals
2016
Peter PowchikRegeneron Pharmaceuticals
2006
Michael StewartPerrigo Company plc
2004
K RaoDr Reddys Laboratories Ltd
2016
Joseph LaRosaRegeneron Pharmaceuticals
2019
George YancopoulosRegeneron Pharmaceuticals
2016
Andrew FentonZoetis
2018
Saumen ChakrabortyDr Reddys Laboratories Ltd
2018
Roman TrawickiZoetis
2015
Scott JamisonPerrigo Company plc
2011
Sripada ChandrasekharDr Reddys Laboratories Ltd
2013
Ganadhish KamatDr Reddys Laboratories Ltd
2016
Paul WeningerPerrigo Company plc
2015
Alok SonigDr Reddys Laboratories Ltd
2015
Sandra BeatyZoetis
2012
Stefan WeiskopfZoetis
2013
Grainne QuinnPerrigo Company plc
2016

Entity Summary

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 2500 people.Vertex Pharmaceuticals Incorpor (VRTX) is traded on BATS Exchange in USA and employs 2,500 people.

Vertex Pharmaceuticals Leadership Team

William Young, Independent Director
Reshma Kewalramani, Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
Michael Parini, Executive Vice President and Chief Legal Officer
Alan Garber, Independent Director
Joshua Boger, Executive Director and Chairman of Science and Technology Committee
John Gray, Senior Vice President Genetic Therapies
Margaret McGlynn, Independent Director
Sangeeta Bhatia, Director
Terrence Kearney, Independent Director
Ian Smith, CFO, Executive Vice President
Paul Silva, Senior Vice President Corporate Controller
David Altshuler, Independent Director
Jeffrey Chodakewitz, Chief Medical Officer and Senior Vice President - Global Medicines Development
Elaine Ullian, Co-Lead Independent Director
Amit Sachdev, Senior Vice President - Global Government Strategy, Market Access and Value
David Greenway, Director
Charles Wagner, CFO, Executive Vice President
Bruce Sachs, Co-Lead Independent Director
Lloyd Carney, Independent Director
Michael Partridge, Vice President - Investor Relations
Yuchun Lee, Independent Director
Kimberly White, Senior Vice President and Chief Communications Officer
Stuart Arbuckle, Chief Commercial Officer and Executive VP
Thomas Graney, CFO, Senior Vice President
Charles Milstein, Executive Vice President Chief Legal and Administrative Officer
Jeffrey Leiden, Chairman of the Board and Presidentident, CEO

Stock Performance Indicators

Did you try this?

Run Content Syndication Now

   

Content Syndication

Quickly integrate customizable finance content to your own investment portal
All  Next Launch Module

Also Currentnly Active

Purchased one share of
few hours ago
Traded for 1221.15
Purchased over 100 shares of
few hours ago
Traded for 19.55
Purchased over 40 shares of
few hours ago
Traded for 43.23
Also please take a look at World Market Map. Please also try Crypto Portfolio Optimizer module to optimize portfolio of digital coins and token across multiple currency and exchanges.
Search macroaxis.com